JUL-16-2003 WED U3:35 PM AMGEN

TIT COMBINATION THERAPY USING AN IL-1 INHIBITOR FOR TP TING INVENTORS: Bendele, et al. APPLN. NO.: A-398F

FIG. 1

M _n	R	P	S	G	R	ĸ	s	s	K	M	Ō	A	F	R	1	W	D	V	И
CA	GAA	GAC	CTI	CTA	TCT	GAG	GAA	CAA	CCA	ACT	AGT	TGC	TGG	ATA	CTI	GCA	AGG	ACC	AAAT
Q	ĸ	T	F	Y	L	R	N	N	Q	L	v	A	G	Y	L	Q	G	P	N
GT	CAA	TTT	AGA	AGA	AAA	GAT	'AGA	TGI	GGT	ACC	CAT	TGA	GĆC	TCA	TGC	TCT	GTT	CTI	'GGGA
V	N	L	E	E	ĸ	I	ם	v	v	₽	I	E	P	н	A	L	F	L	G
AΤ	CCA	TGG	AGG	GAA	GAT	GTG	CCI	GTC	CTG	TGT	CAA	GTC	TGG	TGA	TGA	GAC	CAG	ACT	CCAG
					~														
I	H	Ģ	G	K	M	C	L	S	C	V	ĸ	\$	G	D	E	T	R	L	Q
_				-		•	L TGA	_	C GAG	V CGA	••	_	_	-	_	-		L CTT	cecc
ct 				-		•	L TGA	_	C GAG S	V CGA +	••	_	_	-	_	-		L CTT 	
CT L	GGA E	GGC A	AGT ~+- V	TAA -~- N	CAT	CAC + T	D	CCT L	S	+ E	GAA N	CAG R	ДДД -+- К	GCA Q	GGA D	CAA + K	GCG R	F	cecc
CT L	GGA E	GGC A	AGT ~+- V	TAA -~- N	CAT	CAC + T	D	CCT L	S	+ E	GAA N	CAG R	ДДД -+- К	GCA Q	GGA D	CAA + K	GCG R	F	CGCC A
CT L TT F	GGA E CAT	GGC A CCG	AGT V CTC -+- S	TAA N AGA	CAT I CAG	CAC T T TGG	D CCC	CAC	SCAC	CAG	GAA N TTT F	CAG R TGA	AAA -+- K GTC -+- S	GCA Q TGC	GGA D CGC	CAA K CTG	GCG R CCC	F CGG	CGCC A TTGG
CT L TT F	GGA E CAT	GGC A CCG	AGT V CTC -+- S	TAA N AGA	CAT I CAG	CAC T T TGG	D CCC	CAC	SCAC	CAG	GAA N TTT F	CAG R TGA	AAA -+- K GTC -+- S	GCA Q TGC	GGA D CGC	CAA K CTG	GCG R CCC	F CGG	CGCC A TTGG
CT L TT F	GGA E CAT I CCT	GGC A CCG R CTG	AGT V CTC. S CAC.	TAA N AGA D AGC	CAT I CAG S GAT	CAC TGG TGG GGA GGA E	D CCC P AGC	CAC T TGA	S CAC T	CAG + S GCC +	GAA N TTT F CGT	CAG R TGA E CAG	AAA -+- K GTC -+- S CCT -+- L	GCA Q TGC A CAC	GGA D CGC A CAA	CAA K CTG C-+ C	R CCC P	F CGG G TGA	CGCC A TTGG TTGG W





FIG.

IL-1RA+0.06 MTX 18% PSO.05 2 TAILED T TEST ON RAW DATA, COMP. TO ARTHRITIS CONTROL #PS0.05 2 TALLED T TEST ON RAW DATA, COMP. TO COMBO TX. **BODY WEIGHT CHANGE TREATMENT** SPLEEN WEIGHT PAW WEIGHT -15% IL-1RA MTX 0.05 55% 2 8 28 110 2 喜


% INHIBITION FROM ARTHRITIS CONTROL

TITLE COMBINATION THERAPY USING AN IL-1 INHIBITOR FOR TRESING 1 MEDIATED DISEASES INVENTORS: Bendele, et al. APPLN. NO.: A-398F






Ç





TITLE COMBINATION THERAPY USING AN IL-1 INHIBITOR FOR TRE-11 MEDIATED DISEASES INVENTORS: Bendels, et al. APPLN. NO.: A-398F



Clinical severity (area under severity curve)

TITLE COMBINATION THERAPY USING AN IL-1 INHIBITOR FOR TRECING .-1 MEDIATED DISEASES
INVENTORS: Bendele, et al.
APPLN. NO.: A-398F





Clinical severity (area under

TITL OMBINATION THERAPY USING AN IL-1 INHIBITOR FOR TRE NO MEDIATED DISEASES INVENTORS: Bendele, et al. APPLN. NO.: A-398F

